Ask about this productRelated genes to: DNMT3a antibody
- Gene:
- DNMT3A NIH gene
- Name:
- DNA methyltransferase 3 alpha
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 2p23.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-07-15
- Date modifiied:
- 2019-04-23
Related products to: DNMT3a antibody
Related articles to: DNMT3a antibody
- Older patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy (IC) are more likely to have poor outcomes. Ivosidenib is a first-in-class, oral, targeted small-molecule inhibitor of mutated isocitrate dehydrogenase (mIDH1) approved for use with azacitidine, following the AGILE trial (NCT03173248), for the treatment of mIDH1 AML in patients who are unfit for IC. - Source: PubMed
Publication date: 2026/05/10
Wróbel TomaszKalicińska Elzbieta - Jianpi Qinghua Granule (JPQH) is a hospital-prepared traditional Chinese medicine formula used for insulin resistance and related metabolic disorders. However, its pharmacodynamic basis and epigenetic mechanisms in metabolic dysfunction-associated fatty liver disease (MAFLD) remain unclear. - Source: PubMed
Publication date: 2026/05/08
Xiao YanyanWu HuayiJu WenXiongXu JunfeiChen ChiAbuduhelili BilikeziCai MengjieJin ShenyiYin QinyiTian JingLu HaoHan Xu - Acute myeloid leukemia (AML) is a heterogeneous malignancy with a poor prognosis. Genetic and molecular profiling help guide treatment decisions, including the use of allogeneic hematopoietic stem cell transplantation (allo-HSCT), to reduce relapse risk. This study evaluated the impact of individual and co-mutational genetic profiles in AML patients in first complete remission after receiving allo-HSCT using data from the PETHEMA registry. A retrospective analysis assessed overall survival and relapse-free survival (RFS). Cox regression identified significant variables used to develop a risk score based on hazard ratios, incorporating age, AML type, transplant timing, and genetic/molecular alterations. A total of 717 patients (median age 56.5 years) were included, most classified as adverse risk by ELN2022 criteria. Both ELN2017 and ELN2022 risk classifications were validated. Multivariate analysis showed that DNMT3A, SF3B1, TP53, and WT1 mutations were linked to shorter RFS, whereas FLT3-ITD mutations correlated with prolonged RFS. These findings were integrated into a proposed prognostic score, which was validated. Therefore, this study highlights the prognostic importance of genetic mutations in AML patients undergoing allo-HSCT. These insights could inform pre-transplant strategies, including donor selection and conditioning regimens, as well as post-transplant maintenance therapy. - Source: PubMed
Publication date: 2026/05/07
Colmenares RafaelBarragán EvaRodríguez-Veiga RebecaTorres-Miñana LauraSánchez-García JoaquínTormo MarBernal TeresaMartínez-Sánchez PilarRodríguez-Arbolí EduardoGil CristinaSoria-Saldise ElenaSerrano JosefinaColorado MercedesGarcía-Fortes MaríaBilbao CristinaLópez-Lorenzo José LuisLarráyoz María JoséPérez-Santaolalla EstherLavilla-Rubira EsperanzaAlgarra LorenzoGarcía-Garay María CarmenChillón CarmenTorres-Ochando MelissaCouto CarmenGarcía-Boyero RaimundoAlmela ÁgataNoriega VíctorCallejas MartaBarrios ManuelCasado SoledadBalerdi AmaiaCabello AnaLabrador JorgeMateos María CarmenAmigo María LuzPérez-Encinas ManuelGarcía-Pérez María JoséCostilla LissetteBergua JuanCarreño-Tarragona GonzaloMartínez-López JoaquínAyala RosaMontesinos Pau - Response rates in platinum-resistant ovarian cancer remain low (16-30%) and decline with subsequent lines of therapy. Mirvetuximab soravtansine (MIRV), an antibody-drug conjugate targeting folate receptor alpha (FRα), has demonstrated clinically meaningful activity in FRα-positive disease. We report a 65-year-old patient with heavily pretreated, FRα-positive ovarian cancer who developed therapy-related myelodysplastic syndrome with increased blasts (MDS-IB2, DNMT3A-mutated) during therapy with MIRV in combination with carboplatin having received prior PARPi maintenance therapy. Azacitidine treatment induced complete hematologic remission. Following progression of the ovarian cancer disease, MIRV was reintroduced concurrently with ongoing azacitidine. This strategy resulted in seven months of sustained disease control of the ovarian cancer without evidence of MDS worsening. In fact, after three cycles of azacitidine, a follow-up bone marrow biopsy showed no residual MDS. This case demonstrates that MIRV can be safely and effectively administered alongside azacitidine, providing clinically meaningful tumor control without compromising hematologic outcomes. These findings support the concurrent management of ovarian cancer and therapy-related MDS as a viable and underutilized treatment approach in a highly challenging clinical setting. - Source: PubMed
Publication date: 2026/04/20
Njonou Noujiep Sophonie ShiloniteAltmann JudithBullinger LarsSehouli Jalid - Although next-generation sequencing (NGS) has allowed for the detection of mutations in acute myeloid leukemia (AML), the clinical relevance of variant allele frequency (VAF) for the majority of mutations is unknown. This study aimed to investigate whether the VAFs of AML-associated mutations could improve the prognostic classification in AML. - Source: PubMed
Publication date: 2026/05/05
Zhao LiCheng FengWei JinmingLiu RimingZhao QiZhang YanhongLi Yulan